Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats.

alpha-Methyldopamine (alpha-MeDA) is a metabolite of the serotonergic neurotoxicants 3,4-(+/-)-(methylenedioxy)amphetamine (MDA) and 3,4-(+/-)-(methylenedioxy)methamphetamine (MDMA). alpha-MeDA readily oxidizes, and in the presence of glutathione (GSH) it forms 5-(glutathion-S-yl)-alpha-methyldopamine [5-(glutathion-S-yl)-alpha-MeDA]. Since GSH conjugates of many polyphenols are biologically (re)active, we investigated the role of 5-(glutathion-S-yl)-alpha-MeDA in the acute and long-term neurochemical changes observed after administration of MDA. Intracerebroventricular (icv) administration of 5-(glutathion-S-yl)-alpha-MeDA (720 nmol) to male Sprague-Dawley rats produced behavioral changes similar to those reported after subcutaneous administration of MDA. Thus, animals became hyperactive and aggressive and displayed forepaw treading and Straub tails, behaviors usually seen after administration of serotonin (5-HT) releasers, and consistent with a role for 5-(glutathion-S-yl)-alpha-MeDA in some of the behavioral alterations seen after administration of MDA and MDMA. In addition to the behavioral changes, 5-(glutathion-S-yl)-alpha-MeDA also caused short-term alterations in the dopaminergic, serotonergic, and noradrenergic systems. An increase in dopamine synthesis appears to be a prerequisite for the long-term depletion of brain 5-HT following MDMA administration. However, although 5-(glutathion-S-yl)-alpha-MeDA reproduced some of the effects of MDA on the dopaminergic system and was capable of causing acute increases in 5-HT turnover, a single icv injection of 5-(glutathion-S-yl)-alpha-MeDA did not result in long-term serotonergic toxicity. Thus, although acute stimulation of dopamine turnover may be necessary for long-term serotonergic toxicity, such changes are not sufficient to produce these effects. The effects of a multiple dosing schedule of 5-(glutathion-S-yl)-alpha-MeDA will therefore require investigation before we can define a role for this metabolite in MDA and MDMA mediated neurotoxicity. MDA also produces a pressor response that is related to its ability to release neuronal norepinephrine stores, and 5-(glutathion-S-yl)-alpha-MeDA caused comparable depletions of brain norepinephrine concentrations, indicating that both compounds produce similar effects on the noradrenergic system.

[1]  R. T. Miller,et al.  Metabolism of 5-(glutathion-S-yl)-alpha-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. , 1995, Chemical research in toxicology.

[2]  K. Davison,et al.  Metabolism of 2-(glutathion-S-yl)hydroquinone and 2,3,5- (triglutathion-S-yl)hydroquinone in the in situ perfused rat kidney: relationship to nephrotoxicity. , 1994, Toxicology and applied pharmacology.

[3]  T. Monks,et al.  Metabolism and toxicity of 2-bromo-(diglutathion-S-yl)-hydroquinone and 2-bromo-3-(glutathion-S-yl)hydroquinone in the in situ perfused rat kidney. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[4]  T. Monks,et al.  Oxidation and acetylation as determinants of 2-bromocystein-S-ylhydroquinone-mediated nephrotoxicity. , 1994, Chemical research in toxicology.

[5]  J. Brodkin,et al.  Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity , 1993, Pharmacology Biochemistry and Behavior.

[6]  N. Guo,et al.  Glutathione: New candidate neuropeptide in the central nervous system , 1992, Neuroscience.

[7]  N. Kaplowitz,et al.  Transport of glutathione at blood-brain barrier of the rat: inhibition by glutathione analogs and age-dependence. , 1992, The Journal of pharmacology and experimental therapeutics.

[8]  K. Hashimoto,et al.  Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain , 1992, Brain Research.

[9]  R. Quirion,et al.  Modulatory Role of Glutathione on μ‐Opioid, Substance P/Neurokinin‐1, and Kainic Acid Receptor Binding Sites , 1992, Journal of neurochemistry.

[10]  M. Cuénod,et al.  Screening of Thiol Compounds: Depolarization‐Induced Release of Glutathione and Cysteine from Rat Brain Slices , 1992, Journal of neurochemistry.

[11]  E. Azmitia,et al.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. , 1992, European journal of pharmacology.

[12]  G. Ricaurte,et al.  Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.

[13]  A. Cho,et al.  Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. , 1992, Chemical research in toxicology.

[14]  M. Molliver,et al.  Cytopathologic Features Indicative of 5‐Hydroxytryptamine Axon Degeneration Are Observed in Rat Brain after Administration of d‐ and l‐Methylenedioxyamphetamine a , 1992, Annals of the New York Academy of Sciences.

[15]  G. Hanson,et al.  Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. , 1992, The Journal of pharmacology and experimental therapeutics.

[16]  T. Monks,et al.  Stimulation of N-methyl-D-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione. , 1992, Molecular pharmacology.

[17]  C. J. Schmidt,et al.  L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. , 1991, European journal of pharmacology.

[18]  A. Cho,et al.  Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations. Participation of different cytochrome P450 isozymes in the demethylenation reaction. , 1991, Biochemical pharmacology.

[19]  A. Cho,et al.  Transformation of dopamine and alpha-methyldopamine by NG108-15 cells: formation of thiol adducts. , 1991, Chemical research in toxicology.

[20]  A. Winstock.  Chronic paranoid psychosis after misuse of MDMA. , 1991, BMJ.

[21]  A. Cho,et al.  Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. , 1991, Chemical research in toxicology.

[22]  U. McCann,et al.  Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons , 1991, Brain Research.

[23]  J. Fitzgerald,et al.  Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. , 1990, European journal of pharmacology.

[24]  A. Cho,et al.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.

[25]  N. Kaplowitz,et al.  Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. , 1990, The Journal of clinical investigation.

[26]  E. Pileblad,et al.  Reduction of Brain Glutathione by l‐Buthionine Sulfoximine Potentiates the Dopamine‐Depleting Action of 6‐Hydroxydopamine in Rat Striatum , 1989, Journal of neurochemistry.

[27]  Y. Yoneda,et al.  Apparent binding activity of [3H]glutathione in rat central and peripheral tissues , 1988, Neurochemistry International.

[28]  R. Foltz,et al.  In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.

[29]  C. J. Schmidt,et al.  Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. , 1988, European journal of pharmacology.

[30]  T. Monks,et al.  2-Bromo-(diglutathion-S-yl)hydroquinone nephrotoxicity: physiological, biochemical, and electrochemical determinants. , 1988, Molecular pharmacology.

[31]  G. Hanson,et al.  Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.

[32]  B. Logan,et al.  Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. , 1988, European journal of pharmacology.

[33]  J. Langston,et al.  Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.

[34]  Peroutka Sj.  Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. , 1987 .

[35]  W. Lovenberg,et al.  In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.

[36]  Rudy M. Baum,et al.  New Variety of Street Drugs Poses Growing Problem: Designer drugs—analogs of compounds with proven pharmacological activity made by underground chemists—present novel challenges to law enforcement officials, legislators, and scientists , 1985 .

[37]  L. Seiden,et al.  Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.

[38]  H. Sies,et al.  Hepatic low-level chemiluminescence during redox cycling of menadione and the menadione-glutathione conjugate: relation to glutathione and NAD(P)H:quinone reductase (DT-diaphorase) activity. , 1983, Archives of biochemistry and biophysics.

[39]  K. Midha,et al.  alpha-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[40]  W. Oldendorf,et al.  Blood-brain barrier restriction of peptides and the low uptake of enkephalins. , 1978, Endocrinology.

[41]  William H. Oldendorf,et al.  [3H]Tryptamine and 3H-water as diffusible internal standards for measuring brain extraction of radio-labeled substances following carotid injection , 1976, Brain Research.

[42]  M J Welch,et al.  Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. , 1976, The American journal of physiology.

[43]  J. Elce.  Metabolism of a glutathione conjugate of 2-hydroxyoestradiol-17 in the adult male rat. , 1972, The Biochemical journal.

[44]  D. Grahame-Smith.  STUDIES IN VIVO ON THE RELATIONSHIP BETWEEN BRAIN TRYPTOPHAN, BRAIN 5‐HT SYNTHESIS AND HYPERACTIVITY IN RATS TREATED WITH A MONOAMINE OXIDASE INHIBITOR AND L‐TRYPTOPHAN , 1971, Journal of neurochemistry.

[45]  H. Himwich,et al.  Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. , 1969, International journal of neuropharmacology.

[46]  T. Monks,et al.  Glutathione conjugation as a mechanism for the transport of reactive metabolites. , 1994, Advances in pharmacology.

[47]  J. E. Wolff,et al.  Gamma-glutamyl transpeptidase activity in brain microvessels exhibits regional heterogeneity. , 1992, Journal of neurochemistry.

[48]  G. Ricaurte,et al.  Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. , 1992, Chemical research in toxicology.

[49]  T. Monks,et al.  The role of gamma-glutamyl transpeptidase in hydroquinone-glutathione conjugate mediated nephrotoxicity. , 1991, Advances in experimental medicine and biology.

[50]  S. Peroutka.  Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. , 1987, The New England journal of medicine.

[51]  V. Distefano,et al.  PHARMACOLOGICAL EFFECTS OF (±)-, (S)-, and (R)-MDA*† , 1978 .

[52]  R. Fuller.  Pharmacology of para-chloroamphetamine and analogs. , 1976, Psychopharmacology bulletin.